IMRX
Immuneering Corp
NASDAQ: IMRX · HEALTHCARE · BIOTECHNOLOGY
$5.34
-0.84% today
Updated 2026-05-05
Market cap
$345.48M
P/E ratio
—
P/S ratio
563.62x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $10
Volume
0.9M
Immuneering Corp (IMRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-4.44M | $-14.62M | $-30.85M | $-44.10M | $-48.97M | $-55.00M | $-45.34M |
| Capital expenditures | $20526.00 | $53415.00 | $60786.00 | $742485.00 | $342746.00 | $84875.00 | $142225.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $596631.00 | $1.09M | $1.80M | $4.06M | $5.73M | $6.50M | $6.31M |
| Free cash flow | $-4.46M | $-14.67M | $-30.91M | $-44.84M | $-49.31M | $-55.08M | $-45.49M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $37.80M | $-2.25M | — | — | — |